<img height="1" width="1" src="https://www.facebook.com/tr?id=914352225269004&amp;ev=PageView%20&amp;noscript=1">

Shingles Study

This study aims to evaluate the safety and tolerability of a topical product in reducing the pain associated with shingles.

Shingles is a viral infection that commonly causes a painful, blistering rash on one side of the body, and it typically affects people aged 50 and older or those with weakened immune systems.

Do you suspect you have shingles or have recently been diagnosed? Continue reading for more details and to register your interest.

  • Aged 18 or over
  • Positive shingles diagnosis
  • Symptoms must have started in the past FIVE days
  • VIC
  • NSW
  • Approximately 31 days

Read more
Shingles icon

If you take part in the research study, there will be:


There are no costs associated with participating in this research project, nor will you be paid. You may be reimbursed for any reasonable travel (including Uber) and parking and other expenses associated with the research project visit.


The topical product can be applied at home.

Free study-related medical care

Be among the first to access a potential new treatment before it is widely available.

Expert medical monitoring

Receive top-tier medical care and monitoring from experienced healthcare professionals.

Contribution to medical research

Help investigate a potential new treatment that could provide improved relief from shingles pain.

Register your interest now

or scroll down to read more about this study

About this study


Who can take part in this study?


To take part in this study, you will need to meet all the following:

  • You are aged 18 or over.
  • You have been diagnosed with shingles and have at least three distinct visible lesions on your torso, trunk, arms, or legs.
  • You started experiencing shingles symptoms (lesions/rash) within five days of starting the study.

If you think you might have shingles or have recently been diagnosed, act fast. Register your interest today for a phone screening with our dedicated Patient Experience team. Your participation could play a vital role in shaping the future of shingles care.


Who is unable to take part in this study?


Unfortunately, if any of the following apply to you, this study is not the right fit for you:

  • You have any *significant infection other than shingles.
  • You are taking any medication or drugs that could impact how your body experiences pain - these will be discussed during screening. 
  • You have birthmarks, tattoos, wounds, or other skin blemishes or conditions where the shingles lesions are located - these will be assessed on a case-by-case basis.

*Please note, additional eligibility criteria apply and will be discussed during phone screening with our Patient Experience team. 

Still unsure if this study is suitable for your needs? No worries! Register your interest today for a personalised discussion with our Patient Experience team about your eligibility. 


How long will this study take?


If you are deemed eligible for the study, your participation is expected to last approximately 31 days, and you will be required to attend the study site up to 5 times. This includes: 

  • A site screening visit, which will take about 2 hours.
  • Randomisation and a 10-day treatment period, which includes site visits on Days 1, 5 and 11. Participants will be randomised in a 2:1 ratio to receive the investigational product or a placebo. 
  • A follow-up site visit on Day 30.
  • Over the course of the treatment period, you will be required to apply the investigational product or placebo to the shingles lesions, as well as maintain a diary of your symptoms. 

This is a double-blinded study, which means neither you nor the study doctor will know if you receive the investigational product or a placebo. The placebo looks like the investigational product but does not contain the same active ingredient under investigation.

Researchers use placebos to see what benefits and possible side effects can be attributed to the investigational product. Eligible participants will have a two in three chance of receiving the investigational product.

Participation in this research is voluntary, and you may withdraw from the study at any time.


What is the purpose of this study?


The purpose of this study is to evaluate the safety and tolerability of the investigational product, SolexanTM, its ability to reduce the pain associated with shingles lesions, and to gauge the healing response of the lesions. 

SolexanTM is a white foam that has already been registered by the FDA (Food and Drug Administration) as a topical antifungal, and researchers have gathered early-stage evidence that it may stop the shingles virus from multiplying. It is not currently manufactured for use.


What is shingles?


Shingles is a viral infection that occurs when the varicella-zoster virus, the same virus that causes chickenpox, is reactivated and travels along nerve pathways to cause shingles lesions - painful, fluid-filled blisters that typically appear in a band- or strip-like pattern on one side of the face or body.

The pain associated with shingles lesions is often described as a burning, throbbing, or stabbing sensation, and it can persist for weeks if not months after the lesions have healed.


Why is this study important?


Though the oral antiviral drug Famciclovir  can be used to treat shingles, it must be taken within 72 hours of the first symptom appearing - otherwise, it won’t work as well, and many doctors won’t prescribe this.

However, many patients cannot meet this time frame and so are left with only painkillers for symptom relief. As such, participating in this research study will provide investigators with valuable information about whether Solexan™ is a safe and effective treatment for shingles pain.


Who is sponsoring this study?


This study is sponsored by Wintermute Biomedical, a pharmaceutical company based in Melbourne, Australia, and Missoula, Montana.

Wintermute dedicated its initial decade to researching solutions for drug-resistant infections. They discovered a method to harness the natural germ-fighting properties of fatty acids in common foods.

Collaborating with prestigious institutions like Johns Hopkins Medicine, Public Health England, and the University of Melbourne, Wintermute diligently ensures their solutions prioritise performance to address unmet needs while upholding safety standards for human health and the environment.


Where is my nearest study site?


Here is a list of all the sites currently recruiting for this study:

  • Key Health Sydney CBD Medical Centre:
    • Located in Regency Hyde Park
    • Address: Ground Floor, 281 Elizabeth Street, Sydney NSW 2000, Australia
  • Maxwell Medical Group: 
    • Located in: Central West Shopping Centre
    • Address: T22/65-67 Ashley Street, Braybook VIC 3019, Australia


What if I have other questions about the study?


We are here to help you! Click or tap this button to send an email to our dedicated  Patient Experience team:

Contact us


Further reading:


Help make medical research breakthroughs happen.